We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Seeks to Spur Trial Innovation With Two New Guidances
FDA Seeks to Spur Trial Innovation With Two New Guidances
The FDA might be willing to extrapolate clinical data for targeted therapies even if sponsors can’t recruit patients with a specific genetic variant of the disease being treated, the agency says in the first of two guidance documents issued Monday.